Skip to content
Screener

Monopar Therapeutics MNPR Q4 2024 Annual earnings

Reported March 31, 2025 · Before market open

Revenue-
EPS-$2.23Miss by $1.87
EPS estimate-$0.36

Next report

Nov 6, 2026 (in 3 months)
EPS estimate-$0.77

Financials

Q4 2024

Income statement

See full
Revenue-—
Operating income-$11.1M-479%
Net income-$10.9M-502%

Balance sheet

See full
Cash & equivalents$45.8M+531%
Total equity$55.0M+885%
Total assets$60.3M+721%

Cash flow

See full
Operating cash flow-$2.0M-29.3%

Valuation & ratios

Valuation

as of 12/31/24
See full
Market cap$134.17M+2,553%

Returns & leverage

See full
Return on equity-51.4%-17.6pp
Current ratio11.5×+7.3×

FAQ

When did Monopar Therapeutics report Q4 2024 earnings?
Monopar Therapeutics (MNPR) reported Q4 2024 earnings on March 31, 2025 before market open.
What were Monopar Therapeutics's Q4 2024 revenue and EPS?
Monopar Therapeutics reported revenue of - and eps of $-2.23 for Q4 2024.
Did Monopar Therapeutics beat estimates in Q4 2024?
EPS missed the consensus estimate of $-0.36 by $1.87.
Where can I find Monopar Therapeutics's Q4 2024 SEC filings?
You can read the 8-K earnings release (0001437749-25-009982) and the 10-K periodic report (0001437749-25-009979) directly on SEC EDGAR. The filing index links above go to sec.gov.